Merck will gain the exclusive global license for Chinese drugmaker Hansoh’s HS-10535, an experimental oral drug that targets GLP-1 receptors. Read More
TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.
© 2024 Todayheadline.co